Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Chemoradiotherapy for T4b HNSCC
NCT06725498Phase 2Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Dec 2024
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Beijing Tongren Hospital. Primary endpoint: 1 year Event-free Survival rate. Started Dec 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06725498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06725498.